SeekingAlpha · 20:09 · 06/30 LOW BEARISH

AbbVie shares fell after six-session winning streak

ABBV terminated a six-session rally with a notable reversal, signaling potential profit-taking after a sustained uptrend. The breakdown...

seekingalpha.com · 20:09 · 06/30 NEUTRAL BEARISH

AbbVie shares fell after six-session winning streak (NYSE:ABBV)

ABBV reversed course following a six-session advance, signaling profit-taking behavior after elevated momentum. The pullback arrives...

finance.yahoo.com · 15:41 · 06/29 NEUTRAL NEUTRAL

AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?

AbbVie (ABBV) has achieved a new 52-week high following a substantial 130% appreciation over the past five years, prompting a valuation...

seekingalpha.com · 16:22 · 06/26 NEUTRAL BULLISH

Lilly, J&J, AbbVie hit all-time highs (LLY:NYSE)

Three large-cap Health Care names—Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV)—have reached new 52-week highs, signaling...

insidermonkey.com · 15:48 · 06/26 NEUTRAL NEUTRAL

12 Most Profitable S&P 500 Stocks to Invest In

This article examines shifts in investor focus toward profitability metrics and capital efficiency as selection criteria for S&P 500...

investorideas.com · 16:45 · 06/25 HIGH BULLISH

Definium's Phase 3 LSD Depression Data Stuns the Tape as AbbVie Spends $10.9 Billion on Apogee

Definium's Phase 3 trial success in treating depression with LSD represents a potential therapeutic breakthrough in the psychedelic...

seekingalpha.com · 09:31 · 06/23 HIGH BULLISH

AbbVie Inc. (ABBV) Apogee Therapeutics, Inc. - M&A Call - Slideshow (NYSE:ABBV) 2026-06-23

AbbVie Inc. (ABBV) has disclosed a material M&A transaction involving Apogee Therapeutics, Inc., signaling strategic portfolio expansion...

seekingalpha.com · 21:02 · 06/22 HIGH BULLISH

AbbVie Inc. (ABBV) M&A Call Transcript

AbbVie (ABBV) hosted an M&A-focused investor call on June 22, 2026, signaling active capital allocation strategy and strategic portfolio...

investorideas.com · 15:40 · 06/22 HIGH BULLISH

Monday's Deal Table: AbbVie Buys Apogee for $10.9 Billion and CRH Takes Arcosa for $8.5 Billion, Both All-Cash

ABBV and CRH announced concurrent all-cash acquisition sprees totaling $19.4 billion, signaling aggressive M&A appetite among large-cap...

investorideas.com · 15:40 · 06/22 NEUTRAL BULLISH

Markets Edge Higher as Two Big All-Cash Deals Land and the AI-Memory Trade Heats Up

AbbVie and CRH announced dual all-cash acquisitions totaling $19.4 billion, signaling continued M&A appetite despite macro...

finance.yahoo.com · 14:04 · 06/22 HIGH BULLISH

AbbVie to acquire Apogee Therapeutics in $10.9B deal

AbbVie's $10.9 billion all-cash acquisition of Apogee Therapeutics represents a significant pipeline expansion in high-growth...

rttnews.com · 13:47 · 06/22 HIGH BULLISH

AbbVie To Acquire Immunology Drug Maker Apogee For $10.9 Bln Cash; Shares Climb

AbbVie's $10.9 billion acquisition of Apogee Therapeutics represents a strategic consolidation in the immunology and inflammatory...

CNBC · 13:21 · 06/22 NEUTRAL NEUTRAL

The Club's top 10 things to watch in the stock market Monday

AbbVie (ABBV) is executing on its M&A strategy, signaling continued portfolio consolidation within the pharmaceutical sector. This move...

seekingalpha.com · 11:30 · 06/22 NEUTRAL BULLISH

REGENXBIO’s Duchenne Data Keeps Me Bullish, But There’s Less Room For Setbacks Now (RGNX)

RGNX continues to demonstrate clinical momentum in its gene therapy pipeline, particularly with RGX-202 advancing through Phase 3 trials...

finance.yahoo.com · 10:35 · 06/22 LOW BULLISH

5 Dividend Stocks to Buy and Hold Forever

This article presents a thematic investment strategy centered on dividend-yielding equities as vehicles for long-term wealth...

finance.yahoo.com · 20:17 · 06/21 NEUTRAL NEUTRAL

The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

The Health Care Select Sector SPDR ETF (XLV) faces a pivotal inflection point heading into 2026, with the sector's relative performance...

insidermonkey.com · 17:05 · 06/20 LOW BULLISH

12 High Quality Stocks to Buy for the Long Term

This article reflects a shift in investor preference toward quality-focused equity selection, emphasizing earnings sustainability over...

SeekingAlpha · 11:56 · 06/20 HIGH BULLISH

AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics

AbbVie's reported pursuit of a $10.9 billion acquisition of Apogee Therapeutics signals aggressive portfolio expansion in dermatology...

seekingalpha.com · 13:51 · 06/19 NEUTRAL BULLISH

AbbVie: Immunology Cash Flow Funds Oncology Expansion (NYSE:ABBV)

AbbVie is positioning its portfolio strategically by leveraging strong cash generation from its established immunology franchise to fund...

finance.yahoo.com · 17:34 · 06/17 NEUTRAL BULLISH

AbbVie Inc. (ABBV) Presents Data on Fixed-Duration Venetoclax-Based Combination

AbbVie disclosed Phase 3 efficacy and safety data for a fixed-duration venetoclax-based regimen targeting previously untreated chronic...

seekingalpha.com · 21:31 · 06/16 NEUTRAL BULLISH

AbbVie: Maintaining My Strong Buy Rating After Label Expansion (NYSE:ABBV)

AbbVie (ABBV) faces a critical inflection point as its blockbuster Humira patent cliff accelerates revenue headwinds. The label...

finance.yahoo.com · 17:30 · 06/16 NEUTRAL BULLISH

AbbVie Stock Will Hit $300 on This Date

AbbVie (ABBV) reported Q1 2026 results that exceeded internal expectations, with management signaling a strong operational start to the...

finance.yahoo.com · 11:12 · 06/16 LOW NEUTRAL

FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026?

This comparative analysis examines FHLC and IYH, two healthcare-focused exchange-traded funds, through the lens of portfolio composition...

seekingalpha.com · 18:54 · 06/11 NEUTRAL BULLISH

AbbVie: Growth-Pharma Profile At A Value-Pharma Price (NYSE:ABBV)

AbbVie (ABBV) is characterized as trading at a structural valuation discount despite possessing fundamental attributes typical of...